Core Insights - Treace Medical Concepts, Inc. has launched the limited market release of the Percuplasty Percutaneous 3D Bunion Correction System, following the introduction of other innovative products aimed at enhancing surgical procedures in the foot and ankle sector [1][4][6]. Company Developments - The Percuplasty System is designed for minimally invasive correction of bunion deformities, allowing for precise 3D corrections through small incisions, which reduces pain and recovery time compared to traditional surgeries [6][7]. - The system targets a significant market, with nearly 450,000 bunion surgeries performed annually in the U.S., 70% of which involve metatarsal osteotomies, positioning Treace Medical to capture a larger market share and increase revenues [8]. - The company anticipates full commercialization of the Percuplasty System in the second half of 2025 [2]. Financial Performance - Treace Medical currently has a market capitalization of $492.2 million, with a Zacks Consensus Estimate for fiscal 2024 revenues at $207.6 million, reflecting a growth of 10.9% from fiscal 2023 [5]. Industry Outlook - The global bunion correction systems market is projected to reach $1.2 billion by 2030, with a compound annual growth rate (CAGR) of 6.9% from 2023 to 2030, driven by the rising prevalence of bunions and an increasing number of procedures [9].

PONTE VEDRA, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, beginning at approximately 9:00 am ...

Company Overview - Treace Medical Concepts Inc is a medical technology company focused on advancing the surgical management of bunion and related midfoot deformities [13] - The company has pioneered and patented the Lapiplasty 3D Bunion Correction System, which addresses the root cause of bunions [13] - Treace estimates that 1 1 million of the 67 million Americans affected by bunions are annual surgical candidates [13] - The company has introduced additional products including the Adductoplasty Midfoot Correction System and SpeedPlate Rapid Compression Implants [13] Product Development - The Percuplasty Percutaneous 3D Bunion Correction System represents the company's second entry into the metatarsal osteotomy segment, which accounts for approximately 70% of the 450,000 bunion surgeries performed annually in the US [2] - Full commercialization of the Percuplasty System is anticipated in the second half of 2025 [10] - The Percuplasty System follows the limited release of the Nanoplasty System, providing an additional solution in the large metatarsal osteotomy segment of the $5B+ US bunion market opportunity [12] Market Strategy - The limited market release of the Percuplasty System positions the company to significantly increase its share of the overall bunion market and expand its surgeon customer base [17] - The company aims to provide a comprehensive portfolio of instrumented 3D bunion systems to meet the evolving needs of surgeons and patients [12] - The Percuplasty System is designed to expand surgeon and patient access to the improved recovery and cosmetic benefits of percutaneous bunion surgery [15] Industry Context - Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot [13] - The metatarsal osteotomy segment is the largest segment of the bunion market [2] - There is growing patient demand for minimally invasive (MIS) bunion surgery [15]

PONTE VEDRA, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases utilizing SpeedPlate™ MicroQuad™ implants. The MicroQuad™ implant expands upon the broad utility of the SpeedPlate™ platform, which is ...

Core Insights - Treace Medical Concepts has successfully completed the first cases using IntelliGuide™ PSI technology with the Adductoplasty® System for personalized correction of midfoot deformities [1][2] - IntelliGuide™ PSI is the first patient-specific cut guide system in the U.S. for bunion and midfoot deformities, utilizing AI to create a pre-operative surgical plan from CT scans [2] - The company plans to progressively expand access to IntelliGuide™ for both Lapiplasty® and Adductoplasty® procedures, with a full market release expected in the first half of 2025 [2] Company Overview - Treace Medical Concepts focuses on advancing surgical treatment standards for bunions and related midfoot deformities, affecting approximately 67 million Americans, with an estimated 1.1 million being surgical candidates annually [6][7] - The company has developed the Lapiplasty® 3D Bunion Correction® System, which addresses all three planes of bunion deformities and secures the unstable joint [7] - Treace has also introduced the Adductoplasty® Midfoot Correction System and SpeedPlate™ Rapid Compression Implants to enhance surgical correction and fixation across various procedures [7] Market Position and Future Plans - The introduction of IntelliGuide™ PSI is expected to strengthen Treace's market leadership in the surgical management of bunion and midfoot deformities [3] - The company aims to build a comprehensive portfolio of digital technologies to meet the evolving needs of surgeons and patients [3] - Surgeons have expressed optimism about the potential of IntelliGuide™ PSI to revolutionize treatment approaches for complex foot deformities [3]

Core Viewpoint - Treace Medical Concepts, Inc. has appointed Guy Guglielmino as Chief Commercial Officer to lead its commercial efforts and drive innovation, product commercialization, and growth in the surgical treatment of bunions and midfoot deformities [1][2]. Company Overview - Treace Medical Concepts is focused on advancing the standard of care for surgical management of bunions and related midfoot deformities, which affect approximately 67 million Americans, with an estimated 1.1 million being annual surgical candidates [5]. - The company has developed the Lapiplasty® 3D Bunion Correction® System, which addresses the root cause of bunions by correcting deformities in all three planes and securing the unstable joint [5]. - Treace has also introduced the Adductoplasty® Midfoot Correction System for surgical correction of midfoot deformities and the SpeedPlate™ Rapid Compression Implants for various bone fusion procedures [5][6]. Leadership Appointment - Guy Guglielmino brings extensive experience in the medical technology industry, having previously served as President of Recovery Sciences at Enovis and held senior marketing roles at other notable companies [2]. - His appointment is expected to enhance Treace's market growth and innovation capabilities, aligning with the company's mission to meet customer needs and establish new market standards [2].

Core Insights - Treace Medical Concepts, Inc. is participating in the Stifel 2024 Healthcare Conference with a fireside chat featuring CEO John T. Treace and CFO Mark L. Hair on November 19, 2024 [1] Company Overview - Treace Medical Concepts is focused on advancing surgical treatment for bunions and related midfoot deformities, impacting approximately 67 million Americans, with an estimated 1.1 million being annual surgical candidates [4] - The company has developed the patented Lapiplasty® 3D Bunion Correction® System, which addresses the root cause of bunions by correcting deformities in three planes and stabilizing the affected joint [4] - Treace has also introduced the Adductoplasty® Midfoot Correction System for surgical correction of midfoot deformities and the SpeedPlate™ Rapid Compression Implants for versatile fixation across various procedures [4]

Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.41%. A quarter ago, it was expected that this orthopedic medical device maker would post a loss of $0.29 per share when it actually produced a loss of $0.34, delivering a surprise of -17.24%.Over the last four qu ...

PONTE VEDRA, Fla., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Revenue of $45.1 million in third quarter 2024 increased 11% over same period in 2023Third qua ...

LOS ANGELES, Oct. 23, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ: TMCI) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.If you are a shareholder who suffered a loss, click here to participat ...